Most patients start seeing changes within 812 weeks, with more noticeable weight loss at 36 months
Tirzepatide: This dual agonist of GLP-1 and GIP delivers superior glycemic control and weight reduction, setting it apart as the latest innovation in this drug class
So there may be a little prophylactic ultrasound being done just to be sure, especially if theres any family history of thyroid problems, which are very common and are usually not related to thyroid cancer
This increase gradually reduces your appetite, also helping reduce your weight by 3% to 5% from your normal weight Phase 3: dosage increase of 0.5 mg (for week 9 to 12) Intake 1mg for once in a whole week
NEJM 2025 (REDEFINE-2) Novo Nordisk FDA NDA submission announcement (December 18, 2025) Eli Lilly TRIUMPH-4 topline results (December 2025) Frequently Asked Questions Retatrutide produces higher weight loss at 28.7% versus CagriSema's 20.4%a difference of 21 pounds for a 250-pound person
Benefits for joints and bones: Supports cartilage maintenance and repair Improves joint lubrication Enhances collagen synthesis in tendons and ligaments Promotes bone mineral density Speeds recovery from joint injuries Particularly relevant for: Athletes with chronic joint stress Older adults concerned about osteoporosis Anyone recovering from injury Those with age-related joint deterioration For injury recovery protocols, see our BPC-157 guide , which is often combined with Ipamorelin for comprehensive healing support
